Table 56Summary of included studies. Comparison 55. Augmenting with lithium versus augmenting with a psychological intervention

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Kennedy 2003

RCT

Canada

N=44

Mean age (years): 39.3

Gender (% female): 55

Ethnicity (% BME): NR

Baseline severity: HAMD 11.9 (less severe)

Lithium 600-900mg/day + SSRI/SNRI/moclobemideCBT individual 12 sessions + SSRI/SNRI/moclobemidePartial response (score of 8-15 on HAMD-D) to 1 of 4 standard antidepressant medications (moclobemi de, paroxetine, sertraline, or venlafaxine) to maximum tolerated doses for 8-14 weeks

Treatment length (weeks): 8

Outcomes:

  • Depression symptomatology at:
    • Endpoint
    • 1-month follow-up
  • Depression symptomatology change score
  • Remission
  • Discontinuation due to any reason
  • Discontinuation due to side effects

BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.